A 48-year-old man with a history of recurrent biliary colic presents with jaundice (total bilirubin 4.2 mg/dL, direct 3.8 mg/dL), pale stools, and dark urine. Ultrasound shows multiple gallstones, a dilated common bile duct (8 mm), but no stone is visualized in the duct. What is the most appropriate next investigation to confirm choledocholithiasis?

Explanation

## Investigation of Choice for Suspected Choledocholithiasis **Key Point:** MRCP is the investigation of choice for confirming suspected choledocholithiasis when ultrasound findings are inconclusive. It has 90–95% sensitivity and specificity for detecting common bile duct stones and is non-invasive. ### Clinical Context: Why MRCP? This patient has: - Obstructive jaundice (elevated direct bilirubin) - Dilated common bile duct on ultrasound - No stone visualized in the duct on ultrasound (ultrasound sensitivity for CBD stones is only 60–75%) **High-Yield:** MRCP is a non-invasive, high-resolution imaging modality that directly visualizes the entire biliary tree and pancreatic ducts. It can detect stones as small as 2–3 mm and is superior to ultrasound for CBD stone detection. ### Diagnostic Algorithm for Choledocholithiasis ```mermaid flowchart TD A[Suspected choledocholithiasis]:::outcome --> B{Ultrasound findings?}:::decision B -->|Stone visible in CBD| C[Proceed to ERCP for extraction]:::action B -->|No stone, but dilated duct + jaundice| D[MRCP for confirmation]:::action D --> E{Stone detected?}:::decision E -->|Yes| F[ERCP + sphincterotomy + extraction]:::action E -->|No| G[Investigate other causes of jaundice]:::action F --> H[Cholecystectomy if stones in GB]:::action ``` ### Comparison: MRCP vs. ERCP vs. Ultrasound | Feature | Ultrasound | MRCP | ERCP | |---|---|---|---| | **Sensitivity for CBD stones** | 60–75% | 90–95% | 95–98% (therapeutic) | | **Specificity** | 85–90% | 95–98% | 95–98% | | **Invasiveness** | Non-invasive | Non-invasive | **Invasive** | | **Therapeutic capability** | None | None | **Yes (stone extraction, sphincterotomy)** | | **Pancreatitis risk** | None | None | **3–5%** | | **Radiation** | None | Yes (MRI, no ionizing) | Yes (fluoroscopy) | | **Best use** | First-line screening | **Confirm CBD stones; guide ERCP** | Therapeutic extraction | **Clinical Pearl:** MRCP has largely replaced diagnostic ERCP because it avoids the 3–5% risk of post-ERCP pancreatitis. ERCP is now reserved for therapeutic intervention (stone extraction, stent placement). ### Why MRCP Over ERCP as Next Step? 1. **Non-invasive:** MRCP carries no risk of pancreatitis (ERCP risk: 3–5%). 2. **High diagnostic accuracy:** 90–95% sensitivity and specificity for CBD stones. 3. **Guides management:** If stone is confirmed, ERCP can be scheduled with therapeutic intent. 4. **Cost-effective:** Avoids unnecessary ERCP in patients without CBD stones. **Warning:** Do not perform ERCP as a diagnostic test — it is reserved for therapeutic intervention. Diagnostic ERCP has been replaced by MRCP.